Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal phase III trial of ADVM 022 in wet age-related macular degeneration (AMD)

X
Trial Profile

A pivotal phase III trial of ADVM 022 in wet age-related macular degeneration (AMD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixoberogene soroparvovec (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Adverum Biotechnologies
  • Most Recent Events

    • 08 Feb 2024 According to an Adverum Biotechnologies media release, initiation of Phase 3 trial expected first half of 2025 (H1 25).
    • 01 Mar 2021 According to an Adverum Biotechnologies media release, the company will host a conference call on 1st March 2021 on the ADVM-022 pivotal program for the treatment of wet AMD.
    • 01 Mar 2021 According to an Adverum Biotechnologies media release, the company expects to initiate this trial in Q4 2021. Pending successful outcomes of the trial, Adverum anticipates being able to submit its Biologics License Application for ADVM-022 for wet AMD in 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top